CAR-T therapy utilizing Oncostatin-M ligand demonstrates significant anti-tumor efficacy in osteosarcoma treatment
By
Daniel Feinberg
Vinayak Uppin
Saada Eid
Claire Fritz
Masahiro Hitomi
Akshaya Radhakrishnan
Kayla Klatt
Sung Hee Choi
Jay T Myers
Aarshvi Bhatt
Duncan Stearns
Irina Pateva
Zachary D C Burke
Alex Y Huang
Gary K Schwartz
Reshmi Parameswaran
March 17, 2026
Clinical Scorecard: CAR-T therapy utilizing Oncostatin-M ligand demonstrates significant anti-tumor efficacy in osteosarcoma treatment
At a Glance
Category Detail
Condition Osteosarcoma Key Mechanisms CAR-T therapy targeting Oncostatin-M receptors Target Population Children and adolescents with osteosarcoma Care Setting Clinical trials and research settings
Key Highlights
OSM-CAR-T cells show effective killing of osteosarcoma cells in vitro and in vivo. High expression of OSMR and LIFR on osteosarcoma patient cells suggests promising therapeutic targets. OSM-CAR-T therapy may improve outcomes for osteosarcoma patients with limited treatment options. Guideline-Based Recommendations
Diagnosis
Confirm osteosarcoma diagnosis through histological evaluation. Management
Consider OSM-CAR-T therapy for patients with high OSMR/LIFR expression. Monitoring & Follow-up
Monitor patient response to OSM-CAR-T therapy through imaging and biomarker assessment. Risks
Potential for cytokine release syndrome and other immunotherapy-related adverse effects. Patient & Prescribing Data
Pediatric patients with osteosarcoma, especially those with lung metastasis.
OSM-CAR-T cells demonstrated significant anti-tumor efficacy in preclinical models.
Clinical Best Practices
Utilize patient-derived xenograft models for testing CAR-T efficacy. Ensure thorough patient selection based on OSMR/LIFR expression levels. References
